TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT03123393 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

49

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy of the drug; no safety concern

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG: TAK-659

Sponsor

Calithera Biosciences, Inc